# Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

> **NCT01174199** · PHASE1 · TERMINATED · sponsor: **Roswell Park Cancer Institute** · enrollment: 13 (actual)

## Conditions studied

- Prostate Cancer
- Adenocarcinoma of the Prostate
- Hormone-resistant Prostate Cancer
- Recurrent Prostate Cancer
- Stage IV Prostate Cancer

## Interventions

- **DRUG:** vorinostat
- **DRUG:** temsirolimus
- **OTHER:** laboratory biomarker analysis
- **PROCEDURE:** positron emission tomography/computed tomography

## Key facts

- **NCT ID:** NCT01174199
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-02
- **Primary completion:** 2015-08
- **Final completion:** 2016-08
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** no value in finding efficacy
- **Last updated:** 2022-10-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01174199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01174199, "Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01174199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*